Apogee Therapeutics (APGE) Earnings Date, Estimates & Call Transcripts $37.39 +0.10 (+0.27%) As of 09:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Apogee Therapeutics Earnings Summary Apogee Therapeutics posted Q2 2025 earnings on August 11, 2025, reporting an EPS of -$1.13, which missed the consensus estimate of -$1.03 by $0.10. With a trailing EPS of -$4.13, Apogee Therapeutics' earnings are expected to decrease next year, from ($3.09) to ($3.67) per share. Latest Q2 Earnings DateAug. 11EstimatedConsensus EPS (Aug. 11) -$1.03 Actual EPS (Aug. 11) -$1.13 Missed By -$0.10 Q2 2025 Earnings ResourcesQ2 2025 Earnings Report Press Release (8-K) Quarterly Report (10-Q)Powered by Get Apogee Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Apogee Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataAPGE Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Apogee Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$1.24-$1.24-$1.24Q2 20251-$1.03-$1.03-$1.03Q3 20251-$1.21-$1.21-$1.21Q4 20251-$1.24-$1.24-$1.24 FY 2025 4 -$4.72 -$4.72 -$4.72 Q1 20261-$1.27-$1.27-$1.27Q2 20261-$1.18-$1.18-$1.18Q3 20261-$1.18-$1.18-$1.18Q4 20261-$1.13-$1.13-$1.13 Apogee Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025-$1.03-$1.13 -$0.10-$1.13--5/12/2025Q1 2025-$1.19-$0.95+$0.24-$0.95--3/3/2025Q4 2024-$0.94-$1.19 -$0.25-$1.19--11/12/2024--$0.73-$0.86 -$0.13-$0.86--8/12/2024Q2 2024-$0.60-$0.60--$0.60--5/13/2024Q1 2024-$0.60-$0.64 -$0.04-$0.64--3/5/2024Q4 2023-$0.45-$0.32+$0.13-$0.32--11/13/2023Q3 2023-$0.43-$0.51 -$0.08-$0.51--8/28/2023Q2 2023-$2.49-$3.78 -$1.29-$3.78-- Apogee Therapeutics Earnings - Frequently Asked Questions When did Apogee Therapeutics announce their last quarterly earnings? Apogee Therapeutics (NASDAQ:APGE) last announced its quarterly earning data on Monday, August 11, 2025. Learn more on APGE's earnings history. Did Apogee Therapeutics beat their earnings estimates last quarter? In the previous quarter, Apogee Therapeutics (NASDAQ:APGE) missed the analysts' consensus estimate of ($1.03) by $0.10 with a reported earnings per share (EPS) of ($1.13). Learn more on analysts' earnings estimate vs. APGE's actual earnings. How much profit does Apogee Therapeutics generate each year? Apogee Therapeutics (NASDAQ:APGE) has a recorded net income of -$182.15 million. APGE has generated -$4.13 earnings per share over the last four quarters. What is Apogee Therapeutics' EPS forecast for next year? Apogee Therapeutics' earnings are expected to decrease from ($3.09) per share to ($3.67) per share in the next year. More Earnings Resources from MarketBeat Related Companies Rhythm Pharmaceuticals Earnings Avidity Biosciences Earnings Nuvalent Earnings Axsome Therapeutics Earnings CRISPR Therapeutics Earnings Merus Earnings Viking Therapeutics Earnings TG Therapeutics Earnings ACADIA Pharmaceuticals Earnings Cytokinetics Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Green Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity CrowdStrike Faces Valuation Test Before Key Earnings ReportPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals?Why SoundHound AI's Earnings Show the Stock Can Move Higher This page (NASDAQ:APGE) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access